Maravai LifeSciences (MRVI) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Maravai LifeSciences (MRVI) do?
Maravai LifeSciences Holdings Inc (MRVI) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Manufactures specialized nucleic acids, mRNA capping reagents, and purity testing kits for biopharmaceutical developers. It manufactures chemical capping reagents and analytical test kits required to produce and purify mRNA medicines. It is worth $1.87B on the market and sold $213.11M over the last year.
- Market cap
- $1.87B
- P/E ratio
- None (reported a loss)
- Annual sales
- $213.11M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 19, 2026
Brands and businesses behind MRVI
- TriLink BioTechnologies: It manufactures custom nucleic acids and mRNA capping reagents, earning revenue from research and clinical biopharma contracts.
- Cygnus Technologies: It develops and sells assay kits that measure host cell protein impurities during biologic drug manufacturing.
- Glen Research: It supplies chemical reagents and synthesis tools used to create specialized DNA and RNA oligonucleotides.
- Alphazyme: It develops custom enzyme formulations sold to diagnostic developers and therapeutic nucleic acid producers.
MRVI’s flags, in plain English
Each flag is a number from Maravai LifeSciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.
Stupid Cash
Can pay this year's bills 4.7 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Insiders Hold
Insiders own 25.3% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Burning Cash
Losing money, profit margin of -30.8%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
2 more risk notes open with the free trial. Try it free for 7 days.
Questions about MRVI
How big is Maravai LifeSciences?
Maravai LifeSciences’ market cap is $1.87B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $213.11M: what customers paid the company over the last year, before any costs.
What is MRVI’s P/E ratio?
MRVI has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with MRVI?
Sales have dropped significantly as commercial demand for pandemic-related mRNA vaccines fell sharply from previous highs. That is one risk on Maravai LifeSciences’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Maravai LifeSciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. MRVI’s filings on SEC.gov. The Margin Monkey is research, not advice.
